Scribe Therapeutics Scribe engineers purpose-built CRISPR medicines for widespread use, beginning with a single-dose epigenetic treatment designed to lower LDL cholesterol without permanently changing DNA.
Products & media
Scribe Bets on a New Era of Gene Editing
A clinical-stage, single-dose epigenetic silencing therapy targeting PCSK9 to produce durable LDL cholesterol reduction without permanently changing DNA.
A preclinical X-Editor gene-editing therapy targeting LPA to durably lower lipoprotein(a) in patients with genetically elevated cardiovascular risk.
A preclinical X-Editor gene-editing therapy targeting APOC3 to durably lower triglyceride-rich lipoproteins and reduce pancreatitis and cardiovascular risk.
Team
Jobs
Company history
All fundraising announcements are based on public sources. Please contact Cosign if you believe there are any discrepancies, or claim the profile to edit.
Leads
Participating Firms
Angels
IPO completed · NASDAQ:SCTX